[Lu-177]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study
Singh S, Pavel ME, Kunz PL, De Herder W, Herrmann K, D'Amelio AM, Santoro P, Folitar I, Ferone D (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: LIPPINCOTT WILLIAMS & WILKINS
City/Town: PHILADELPHIA
Pages Range: E58-E58
Conference Proceedings Title: PANCREAS
DOI: 10.1016/s0167-8140(22)04371-7
Authors with CRIS profile
Involved external institutions
Yale University
United States (USA) (US)
Novartis AG
Switzerland (CH)
Universitätsklinikum Essen
Germany (DE)
Ospedale Policlinico San Martino
Italy (IT)
Advanced Accelerator Applications SA
France (FR)
Erasmus University Medical Center (MC)
Netherlands (NL)
University of Toronto
Canada (CA)
United States (USA) (US)
Novartis AG
Switzerland (CH)
Universitätsklinikum Essen
Germany (DE)
Ospedale Policlinico San Martino
Italy (IT)
Advanced Accelerator Applications SA
France (FR)
Erasmus University Medical Center (MC)
Netherlands (NL)
University of Toronto
Canada (CA)
How to cite
APA:
Singh, S., Pavel, M.E., Kunz, P.L., De Herder, W., Herrmann, K., D'Amelio, A.M.,... Ferone, D. (2022). [Lu-177]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study. In PANCREAS (pp. E58-E58). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
MLA:
Singh, Simron, et al. "[Lu-177]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study." Proceedings of the PANCREAS PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2022. E58-E58.
BibTeX: Download